Industry P Pharmaceutical Executive
How Changes in a Tumor Have a Significant Impact on Treatment Options
When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry P Pharmaceutical Executive
When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.
Industry
Pharmaceutical Technology
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of $750m.
Industry
European Biotechnology
Nine reports of tumors in children treated with Novartis' spinal muscular atrophy (SMA) gene therapy Zolgensma raise new questions about its long-term safety. In two cases, viral vector DNA was detected in the patients' genomes. In 2022, two children had already died of acute liv…
Industry P pharmaphorum
UK pilots shorter NICE appraisal for new medicines Phil.Taylor Fri, 06/11/2026 - 10:23
Industry
European Biotechnology
Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: neuroscience experience for Oculis, an experienced CMO for ARTHEx and manufacturing leadership for CRISPR Therapeut…
Industry
Labiotech
Joining us is Shashi Koduru, Senior Director of Business Development at Vector BioMed. We discuss how he finds the right partners, and makes short meetings productive. The post How to turn a BIO-Europe meeting into a lasting partnership appeared first on Labiotech.eu. © Labiotech…
Industry P Pharmafile
By Mike Morgan-Giles Private prescribing of cannabis-based medicines in the UK has more than doubled in a year. Getting the same treatment on the NHS remains close to impossible — and much of the explanation lies in a mismatch between how these medicines are made and how they’re…
Industry
European Biotechnology
Dutch biotech Anaheim Bio, a spin-out of BioMarin-acquired Alesta Therapeutics, has launched with an oversubscribed €40 million Series A to advance ANA-1, a potential disease-modifying treatment for calcium pyrophosphate deposition disease (CPPD), commonly known as pseudogout, in…
Industry S Science News
In first clinical result using “chemogenetic” strategy, a team in China treated three patients to control epilepsy
Industry
Inside Precision Medicine
Maintenance of higher levels of estrogen—as seen in women who had longer reproductive lifespan, were on hormonal birth control, and later menopause—are connected with healthier blood vessels in the brain later in life. The post Increased Estrogen Over Lifespan Linked to Healthier…
Industry
GEN
NYU Grossman School of Medicine researchers found that DNA-copying problems at a small set of chromosome sites can determine how cancer cells respond to PARP inhibitors, pointing to possible biomarkers of drug sensitivity. The post Where DNA Copying Fails Can Decide How Cancer Ce…
Industry S Science News
Spring strike brought a return to the bargaining table, but negotiations stalled over key demands
Industry F FDA Law Blog
By James E. Valentine & Sarah Wicks —
Industry
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTSITC 2026: ENGINEERING IMMUNE RESPONSES INSIDE TUMORSTumor-homing bacteria, modified immune cells, and genetic therapies offer new ways to overcome immunosuppression
Industry
Nature Biotechnology
Industry
Nature Reviews Drug Discovery
Industry
MedCity News
Growing use of wearable technologies and the data they produce was discussed by a panel at the MedCity News INVEST Digital Health Conference in Dallas. The post Why the Wealth of Data From Wearables Are Important for Consumers and Clinicians appeared first on MedCity News.
Industry
PharmaVoice
A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
Industry
Drug Delivery Business
Tandem Diabetes Care (Nasdaq: TNDM) has named its next president and CEO, as current chief John Sheridan plans to retire at the end of this year. Jeannette Bankes will lead the company starting Nov. 16. Most recently president and CEO of GE HealthCare’s patient care solutions bus…
Industry
BioCentury
BIOCENTURY | EMERGING COMPANY PROFILEALETHIO: A MUTATION-AGNOSTIC APPROACH TO ESSENTIAL THROMBOCYTHEMIAOxford spinout raised $90M to take its platelet receptor antibody through Phase I/IIa
Industry P Pharmaceutical Executive
Pharma leaders on building teams with rigor and trust—and retaining talent by connecting individual growth to mission and patient impact.
Industry P Pharmaceutical Executive
Pharma leaders share how trust, mission alignment, and guiding teams through rapid change—including AI—drive results for patients.
Industry
Bio.News
Orphan drug development is one of the more fraught undertakings in biomedical research. Targeting rare diseases often requires cutting-edge science, but science is not […] The post BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives appe…
Industry
GEN
The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical. The post Boehringer…
Industry
BioPharma Dive
Regulators finalized a rule Wednesday that would slash payments for drugs in the controversial 340B program and equalize some payments between care sites. Hospitals railed against the rule.
Industry P Pharmaceutical Executive
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat on improving how tu…
Industry
Inside Precision Medicine
Researchers used the human pangenome to improve somatic mutation detection, uncovering thousands of previously missed candidate mutations in a melanoma cell line. The post Pangenome Finds Thousands of Cancer Mutations Standard Reference Misses appeared first on Inside Precision M…
Industry
STAT Biotech
Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.
Industry
GEN
The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sourc…
Industry
GEN
Mass spectrometry-based exposomics could be a powerful approach to measuring and understanding environmental impact on health. The post Revealing the Chemistry Around Us Through Mass Spectrometry appeared first on GEN - Genetic Engineering and Biotechnology News.
Industry
BioPharma Dive
J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.
Industry
GEN
Personalized grafts, bioinks, and off-the-shelf tissues are advancing regenerative medicine toward broader clinical use. The post Tissue Engineering Takes Shape appeared first on GEN - Genetic Engineering and Biotechnology News.
Industry
GEN
Genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies—eGenesis, Epicrispr, KOMO Biosciences, and Sumitomo Pharma America—discuss how they are moving beyond conventional CRISPR to develop novel…
Industry A Applied Clinical Trials
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it woul…
Industry
Inside Precision Medicine
A massive dataset has revealed how different patients share the same T-cell receptors against different cancers, revealing the value of computer analysis of information gleaned from routine clinical genomics testing. The post Common T-Cell Receptors Found in Multiple Cancers appe…
Industry B BioPharm International
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
Industry
STAT Biotech
Three years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event. Now, the therapy…
Industry
BioPharma Dive
Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to draw conclusions about the pancreatic cancer drug’s launch trajectory.
Industry
Pharmaceutical Technology
Cordavis was established by CVS Health three years ago to capture more of the US biosimilar supply chain.
Industry
GEN
An oral obstructive sleep apnea therapy targeting multiple pathways is poised to improve patient compliance and, possibly, outcomes. The post Oral Sleep Apnea Therapy Poised to Expand Treatment Options appeared first on GEN - Genetic Engineering and Biotechnology News.